Asthma affects lung function and can lead to symptoms related to airway obstruction. This includes: wheezing, shortness of breath, and breathlessness. Asthma can also lead to a dry cough and in severe cases, difficulty breathing.\n
Patients treated with BTS/budesonide, an acceptable and rigorous therapeutic approach, achieved complete disease control rate. Results from a recent paper suggest that moderate and severe uncontrolled asthma can be effectively controlled with daily dosing of an acceptable dose of corticosteroid under BTS.
Anticholinergics and corticosteroids are the most common prescription drugs prescribed to patients with uncontrolled asthma, but education and asthma control measures are also often used. Antihistamines are not commonly prescribed to patients with asthma in Canada. Some patients have prescribed treatments not proven to be effective, and this has been a cause for concern. The impact of overuse of inhaled corticosteroid prescriptions depends on the definition of "overuse" given in the report: the report of overuse is based on the patient's subjective experience and can be influenced by confounding factors and by non-adherence to prescribed treatment regimens.
Asthma affects around 20 million Americans every year because of wheezing and chronic air flow obstruction. Approximately 2 million are hospitalized because of asthma in a year in the United States. The National Asthma Education Foundation and National Institutes of Health provide educational materials on asthma.
Our answers do not completely match the answers reported in the national and international literature. However, we believe we have captured the general concept behind asthma from the perspective of patients for those who are living with it.
There are several potential causes of asthma. Most asthma occurs in children, and is most frequently associated with the body's response to allergies and other inhaled environmental chemicals. Some causes of asthma can be mitigated, though not entirely reversed. Most of the environmental exposure that is thought to cause asthma, including cigarette smoke, is not, however, reversed by removing smokers from the air they breathe. It is important to make asthma awareness a priority.
Those suffering from asthma usually have to carry the disease at home and have to struggle everyday with the symptoms. Asthma may affect their day-to-day life considerably. Asthma patients have to take the extra effort in carrying out normal activities. This can affect their social life adversely, and may sometimes make it difficult for them to enter the university. In order to reduce the symptoms of asthma, the patient or a caregiver has to give themselves an education about asthma so that they can properly take their medications and take the correct dosages. Asthma is common and it should be treated in the right manner.
Patient and physician views of PEFRs are sufficiently different that there are important differences in the way PEFRs are used for asthma treatment. Current practice of using PEFRs to guide therapy is not consistent with current knowledge and is not based on objective evidence. The current emphasis on PEFRs in asthma treatment may be over-driven by personal experience or lack of objective evidence.
Although the correlation is not 1, there is a strong correlation between the level of PEF and the level of symptoms experienced in asthmatics. A correlation exists between PEF and symptoms with a coefficient of 0.78, which suggests that PEF measurement is a useful tool to monitor symptom status and help to detect asthma flareups. Thus PEF can be considered a useful objective parameter to follow the symptoms objectively in asthmatics. PEF is a significant and useful objective tool that may help establish early treatment, and is likely a clinically useful tool to help tailor inhaled bronchodilator therapy for asthmatics.
There are many different trials concerning PEF measurements, though most have been conducted in an outpatient setting in the West. PEF is not used in clinical practice, and clinicians might be concerned that it may compromise patient-provider relationships by interfering with the doctor-patient relationship. Future research should focus on this concern. In addition, since PEF studies have relied heavily on patient self-report questions on the day of enrollment, the degree to which one can assume the validity of the results is limited. Additionally, research is limited in demonstrating what type of self-reported data can be used to assess asthma control. Findings from a recent study was conducted to evaluate the validity of self-reported data.
Results from a recent paper provides a guide on prescribing peak expiratory flow rates for inhaler patients with asthma and the common side effects of PEFR measurement in those with asthma. Clinicians prescribing PEFs for use in patients with asthma, may not always be aware of the possibility of a PEFR > or = 70% of peak of norm. Physicians should be aware that PEFR is not a marker for disease activity.